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Sirs,
We read with great interest the article of Foster et al. [1] on
risk factors for glucorticoid-induced obesity in children
with steroid-sensitive nephrotic syndrome (SSNS). The
prevalence of obesity in patients with remote SSNS was
high with 20%, however, not significantly different from
the prevalence in the reference group. We have recently
reported a comprehensive long-term study on 42 adults
treated for childhood SSNS, providing also a detailed
analysis of growth [2]. The median BMI was 23 kg/m2;
in five women and three men the BMI was >25, and only
one female was obese, with a BMI of 31.4. No correlation
was found between height and weight in adulthood and the
cumulative prednisone dose or duration of prednisone
administration. The epidemic of being overweight and
obese appears to be more prevalent in the US than in some
European countries. We suggest to add to the conclusion of
Foster’s report that the prevalence of persistent obesity in
children with SSNS is also correlated with the local
prevalence or epidemic of obesity in the healthy reference
group.
Also, other clinical endpoints seem to differ in various
geographical areas. Hegarty et al. [3] reported a high
prevalence of bone fractures in adults treated with steroids
for childhood SSNS in the UK: Of the 24 male and 10
female subjects, 19 (79.2%) and 3 (30%), respectively, had
suffered a total of 43 self-reported fractures. In contrast,
only 2 (5%) of the 42 patients in our study had sustained a
single bone fracture although our patients were not given
calcium or vitamin D supplements.
We propose that the long-term outcome and clinical
endpoints in steroid-sensitive idiopathic nephrotic syn-
drome not only depend on treatment regimens and therapy
responsiveness, but also on regional circumstances, life-
styles and living conditions.
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